No Data
When Should You Buy Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)?
Qingdao Haier Biomedical Co., Ltd. (688139.SH): Haichuang Zhitong has completed Shareholding of 1.8% of the company's shares.
Gelonghui reported on April 10 that Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that as of April 10, 2025, Haichuangzhi had increased its shareholding of the company by 5,729,305 shares through the centralized bidding system of the Shanghai Stock Exchange, accounting for 1.8% of the company's total equity, with a total investment of 181.8369 million yuan (excluding transaction costs). This shareholding plan has been fully implemented.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): A total repurchase of 0.165% of shares.
On April 1, Gelonghui reported that Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that as of March 31, 2025, the company has repurchased a total of 524,614 shares through the centralized bidding trading system of the Shanghai Stock Exchange, accounting for 0.1650% of the company's total share capital of 317,952,508 shares. The highest transaction price was 34.69 yuan/share, the lowest price was 31.78 yuan/share, and the total amount paid was 17,467,616.72 yuan (excluding transaction fees).
Haier Biotech 2024 Annual Report Summary
Haier Biotech 2024 Annual Report
Qingdao Haier Biomedical Co., Ltd. (688139.SH) released its performance for the year 2024, with a net income of 0.367 billion yuan, a decrease of 9.71% compared to the previous year.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) disclosed the 2024 annual report, with the company achieving revenue of 22.84...
Market Still Lacking Some Conviction On Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)
